%0 Journal Article
%T Blood Pressure Control with a Single-Pill Combination of Indapamide Sustained-Release and Amlodipine in Patients with Hypertension: The EFFICIENT Study
%A Uday Jadhav
%A Jagdish Hiremath
%A Deepak J. Namjoshi
%A Vinod K. Gujral
%A Kamlakar K. Tripathi
%A Mohammad Siraj
%A Paramesh Shamanna
%A Michel Safar
%J PLOS ONE
%D 2014
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0092955
%X Objective Despite antihypertensive treatment, most hypertensive patients still have high blood pressure (BP), notably high systolic blood pressure (SBP). The EFFICIENT study examines the efficacy and acceptability of a single-pill combination of sustained-release (SR) indapamide, a thiazide-like diuretic, and amlodipine, a calcium channel blocker (CCB), in the management of hypertension. Methods Patients who were previously uncontrolled on CCB monotherapy (BP¡Ý140/90 mm Hg) or were previously untreated with grade 2 or 3 essential hypertension (BP¡Ý160/100 mm Hg) received a single-pill combination tablet containing indapamide SR 1.5 mg and amlodipine 5 mg daily for 45 days, in this multicenter prospective phase 4 study. The primary outcome was mean change in BP from baseline; percentage of patients achieving BP control (BP<140/90 mm Hg) was a secondary endpoint. SBP reduction (¦¤SBP) versus diastolic BP reduction (¦¤DBP) was evaluated (¦¤SBP/¦¤DBP) from baseline to day 45. Safety and tolerability were also assessed. Results Mean baseline BP of 196 patients (mean age 52.3 years) was 160.2/97.9 mm Hg. After 45 days, mean SBP decreased by 28.5 mm Hg (95% CI, 26.4 to 30.6), while diastolic BP decreased by 15.6 mm Hg (95% CI, 14.5 to 16.7). BP control (<140/90 mm Hg) was achieved in 85% patients. ¦¤SBP/¦¤DBP was 1.82 in the overall population. Few patients (n = 3 [2%]) reported side effects, and most (n = 194 [99%]) adhered to treatment. Conclusion In patients who were previously uncontrolled on CCB monotherapy or untreated with grade 2 or 3 hypertension, single-pill combination indapamide SR/amlodipine reduced BP effectively¡ªespecially SBP¡ª over 45 days, and was safe and well tolerated. Trial Registration Clinical Trial Registry ¨C India CTRI/2010/091/000114
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0092955